Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association

Author:

Nakajima Nobuyuki1ORCID,Miyajima Akira1,Shinohara Nobuo23,Obara Wataru24ORCID,Kondo Tsunenori25,Kimura Go26,Kume Haruki27,Fujimoto Hiroyuki28,Sugiyama Takayuki29,Nonomura Norio210,Hongo Fumiya211,Fukumori Tomoharu212,Takahashi Masayuki213,Kanayama Hiro-omi213,Eto Masatoshi214

Affiliation:

1. Tokai University, School of Medicine, Department of Urology, Kanagawa, Japan

2. The Cancer Registration Committee of the Japanese Urological Association, Tokyo, Japan

3. Hokkaido University, Graduate School of Medicine, Department of Renal and Genitourinary Surgery, Hokkaido, Japan

4. Iwate Medical University, School of Medicine, Department of Urology, Iwate, Japan

5. Tokyo Women's Medical University Medical Center East, Department of Urology, Tokyo, Japan

6. Nippon Medical School of Medicine, Department of Urology, Tokyo, Japan

7. The University of Tokyo, Graduate School of Medicine, Department of Urology, Tokyo, Japan

8. National Cancer Center Hospital, Urology Division, Tokyo, Japan

9. Hamamatsu University, School of Medicine Faculty of Medicine, Department of Urology, Shizuoka, Japan

10. Osaka University, Graduate School of Medicine, Department of Urology, Osaka, Japan

11. Kyoto Prefectural University of Medicine, Department of Urology, Kyoto, Japan

12. Tokushima Municipal Hospital, Department of Urology, Tokushima, Japan

13. Tokushima University, Graduate School of Biomedical Sciences, Department of Urology, Tokushima, Japan

14. Kyushu University, Graduate School of Medical Sciences, Department of Urology, Fukuoka, Japan

Abstract

Abstract Background More patients with renal cell carcinoma are now diagnosed with the disease in its early stages. Although patients with pT1a renal cell carcinoma have a good prognosis and low recurrence rate, a few patients still experience recurrence. Herein, we evaluated the clinicopathological risk factors for postoperative recurrence of pT1aN0M0 renal cell carcinoma. Methods An renal cell carcinoma survey was conducted by the Japanese Urological Association to register newly diagnosed cases of renal cell carcinoma. A total of 1418 patients diagnosed with pT1aN0M0 renal cell carcinoma who underwent surgery as the primary surgical treatment were included. We analyzed the recurrence-free survival using the Kaplan–Meier method and clinicopathological factors for recurrence using Cox proportional hazards models. Results Among 1418 patients, 58 (4.1%) had recurrences after a median follow-up of 62.8 months. The median time to recurrence was 31.0 months. Metastases to the lungs and the bone were observed in 20 and 10 cases, respectively. Significant differences in sex, tumor size, Eastern Cooperative Oncology Group performance status, and dialysis history, preoperative hemoglobin levels, C-reactive protein levels and creatinine levels were observed between the recurrence and non-recurrence groups. Multivariate analysis identified male sex, high C-reactive protein level and tumor size ≥3 cm as independent risk factors. The 5-year recurrence-free survival of patients with 0, 1, 2 and 3 risk factors was 99.0, 97.2, 93.1 and 80.7%, respectively. Conclusions Male sex, tumor diameter and a high C-reactive protein level were independent recurrence risk factors for pT1a renal cell carcinoma; special attention should be paid to patients with these risk factors during postoperative follow-up.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3